Biohaven steps up big clinical plans for its reformulated ALS generic — now also aimed at anxiety
Biohaven $BHVN put together a tiny test study to see if their drug BHV-0223 — a reformulation of an old ALS drug called riluzole — could tackle a big potential market: clinical grade anxiety sparked by standing up to give a public speech.
This qualifies as a DSM-5 condition, and investigators lined up 21 patients and divided them into two groups, one of which got the drug before giving a speech and the other a sugar pill.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
